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A COMPARISON OF HIGH-COST HEALTH CARE
PROGRAMS AVAILABLE INTHE BRAZILIAN PUBLIC
HEALTH CARE SYSTEM
Saggia MG
Roche Brazil, Sao Paulo, SP, Brazil
OBJECTIVES: To compare the yearly expenditure per capita of
the following high-cost health care programs available in the
Brazilian public health care system: severe Rheumatoid Arthritis,
renal replacement therapy, Hepatitis, Aids and Oncology.
METHODS: A survey in the ofﬁcial health care database (http://
www.datasus.gov.br) was conducted to gather: 1) the amount of
resources spent (annual budget), and 2) the number of patients
treated in each program in 2007. Those data were then cross-
checked with some public information found in the Ministry of
Health website (www.saude.gov.br) and from medical societies.
For the Aids program an article published by Grangeiro et al. in
2006 was used since it resulted from an extensive research and
both data on drugs expenditure and the number of patients in
2007 were not available in the ofﬁcial health care database.
Based on that article the annual budget and number of patients
for the Aids program were updated by the ofﬁcial inﬂation rate
and the ofﬁcial incidence rate, respectively. Then the yearly
expenditure per capita for each program was calculated. A limi-
tation of this study is the expenditure per capita calculated for
the Oncology program. Since there is no ofﬁcial data regarding
the prevalence of oncological diseases in Brazil only new cases
(incidence) were considered for the calculation, so the ﬁnal
expenditure per capita is likely to be lower than the one calcu-
lated in this study. RESULTS: Severe Rheumatoid Arthritis:
R$82,060,720 for 2,098 patients = R$39,120 per patient per
year (the highest expenditure per capita); renal replacement
therapy: R$1,397,958.956 for 73,605 patients = R$18,993
per patient per year; Hepatitis: R$295,428,000 for 44,598
patients = 6,624 per patient per year; Aids program:
R$1,062,316,834 for 168,417 patients = R$6,308 per patient
per year; Oncology: R$1,026,017,544 for 472,000 patients =
R$2,174 per patient per year (the lowest yearly expenditure per
capita). CONCLUSIONS: Findings indicate signiﬁcant differ-
ences in the yearly expenditure per capita for each program.
Further studies are recommended to extend this analysis and to
explore the reasons for those differences.
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OBJECTIVES: To estimate the daily costs of intensive care unit
(ICU)-stay with a focus on mechanical ventilation (MV) in three
European countries. METHODS: This retrospective cost study
was conducted in one German, one Italian and three Dutch adult
medical-surgery ICUs, from a hospital perspective. A microcost-
ing approach was applied, implying that all relevant cost com-
ponents were identiﬁed and valued at a detailed level. Direct cost
included medical imaging services, laboratory procedures, drugs,
ﬂuids, disposables, inpatient stay, and labour. Indirect costs
consist of overheads and capital. Resource use was primarily
derived from hospital administrative databases. Unit costs were
acquired from ﬁnancial hospital databases and hospital phar-
macy databases. Overheads and capital costs were appointed to
patients using a marginal mark-up percentage. The reference year
was 2006. RESULTS: Total daily costs amounted to €1225 in
Germany, €1472 in Italy and €1911 in The Netherlands, with
labour and overheads as the most important cost drivers. Direct
daily costs were €1040 in Germany, €1333 in Italy and €1243 in
The Netherlands. Hence, the cost differences between the coun-
tries were mainly driven by diverging indirect costs. Mechanical
ventilation in critically ill patients was associated with a 21% to
29% cost increase. CONCLUSIONS: The direct but not the
indirect costs of intensive care are in the same range in Germany,
Italy and The Netherlands. Mechanical ventilation leads to sub-
stantial higher ICU costs.
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COST DRIVERS INTHE PHARMACEUTICAL MARKET IN
GERMANY IN 2007
Häussler B, Höer A
IGES Institut GmbH, Berlin, Germany
OBJECTIVES: To determine the effects of different drivers for
changes of the overall expenses for pharmaceuticals in Germa-
ny’s social health insurance (SHI) from 2006 (26.4 bn Euro) to
2007 (28.0 bn Euro). To determine the role of shifts towards the
prescription of more costly follow-on drugs. METHODS: Analy-
sis was based on sales data on 90,027 different drug preparations
having been prescribed in 2006 and 2007. An overall of 636 m
(2006) resp. 650 m (2007) prescriptions represented 97% of all
drug expenses of the SHI. By calculating index numbers we
estimated the inﬂuences of quantities, prices, and eight structural
components, amid others shifts between classes of drugs as well
as shifts between compounds within classes of drugs. The latter
indicates shifts towards more costly follow-on drugs. Analyses
have been carried out for 95 different indication groups.
RESULTS: Sales increased for 1.6 bn Euro and the prescribed
quantities of drugs for 1.9 bn from 33.2 bn to 35.1 bn DDD. The
higher quantity of prescribed DDD enhanced sales by 2.2 bn
Euro. Reduced prices resulted in savings of 0.2 bn Euro. A higher
cost efﬁciency of prescribing was also achieved by an increased
prescription of generic drugs, larger packages and drugs of higher
dosage strength summing up to savings of about 0.5 bn Euro. In
the two drug groups with the highest quantity of prescribed DDD
(ACE inhibitors: 3.2 bn DDD; statins: 2.1 bn DDD) the propor-
tion of Ramipril and Simvastatin increased from 49 to 57% and
from 79 to 85%, respectively. CONCLUSIONS: The most
important cost driver was the increase of the number of pre-
scribed DDD reﬂecting unserved needs in frequent indications in
former years. Shifts to more costly follow-on drugs had no
impact on the overall costs.
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IS PATENT PROTECTION CREATING OPPORTUNITY FOR
INNOVATION?—THE ALENDRONATE CASE IN BELGIUM
Arickx F, Pierlet M, Soete E,VanHaeren E,Verplanken P,VanWilder P
RIZIV National Health Insurance Agency, Brussels, Belgium
OBJECTIVES: To estimate the budget impact of the reimburse-
ment of a follow-up on patent medicine prior to the patent
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expiry of the original brand, from a third payer’s perspective,
based on the alendronate case. METHODS: The Belgian trade
name for alendronate is Fosamax® (patent expiry: April 2008).
The basis for reimbursement (reference price) for generics is set
by law at minus 30%. The originator company introduced
Fosavance® (ﬁxed combination with vitamin D—patent expiry:
2018) in July 2006. Using registered consumption data from
RIZIV, the evolution of the monthly expenses for alendronates
was considered and expected annual expenses were estimated
with or without the reimbursement of Fosavance®. RESULTS:
The monthly expenses for Fosamax® decreased from €2.7 Mio
prior to the reimbursement of Fosavance® to €1.4 M by July
2007. Simultaneously the expenses for Fosavance® increased to
€1.4 M. Only 52% of the market (in value) is left for generic
competition. The monthly opportunity savings are estimated to
be 30% of €1.4M (€0.52 M) instead of 30% of €2.7 M
(€0.81 M). The opportunity loss is therefore €3.5 M per year
assuming constant market value (137,500 patients treated with
alendronates in 2006). CONCLUSIONS: The alendronate
patent expiry and generic competition would theoretically have
generated an economy of 30% on the entire alendronate
market. The switch to the patent-protected ﬁxed combination
however shelters a substantial part of this market from generic
competition and from the effects of the off-patent reimburse-
ment policy. Therefore, this ‘life cycle management’ technique
jeopardizes the release of ﬁnancial resources and the creation of
budget headroom, essential for ﬁnancing the access to new
and/or innovative medicines. It should be considered as an
opportunity ‘lost’.
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OBJECTIVES: The Hungarian goverment allocates signiﬁcant
investment budget for hospital development between 2008–
2013. A cost-beneﬁt model was developed to assess the social
beneﬁt of public health care investments. We present the results
for a planned investment in a large district hospital with 1586
beds. METHODS: We considered the following long-term social
and ﬁnancial beneﬁts: 1) QALY gain and incremental costs from
new services; 2) cost savings and QALY gain from simpliﬁed
patient routes and reduced postoperative complication; 3)
improved technical efﬁciency of operation (e.g. matrix organiza-
tion); and 4) reduction of ﬁxed costs. Inncremental costs and
beneﬁts are calculated over a 15 year period. We employed 8%
discount rate for costs and 5% for QALYs. Health beneﬁts were
translated to monetary terms by assuming 40,000€/QALY gain
coversion rate. 250 HUF/1€ exchange rate was used in the
model. RESULTS: Our model estimated €8.1 million ﬁnancial
and €43.7 million social beneﬁt over 15 years from the €49.5
million investment. The Net Present Value of the hospital devel-
opment project is €7.5 million (including the remaining value of
assets after 15 years). The investment potentially improves the
sustainabilty of the hospital operation, as the annual net ﬁnancial
balance exceeds the annual cost of depriciation by €800,000.
CONCLUSIONS: Cost-beneﬁt analysis of public investment
projects improves the allocative efﬁciency of scarce resources.
Our model can assess the return on investemnt by capturing
long-term social and ﬁnancial beneﬁts and also the sustainability
of hospital operation. Prospective validation of the model is
necessary.
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OBJECTIVES: To describe the effect of patient’s morbidity load
in relation to resource utilization in Primary Care (measured by
pharmacy cost and visits) trough the retrospective application of
ACG in 23 Primary Care Health Centres from three Spanish
regions. METHODS: Multicentre, retrospective study based on
data from electronic records of patients seeking care during 2005
in the autonomous regions of Aragon, Balearics and Catalonia.
Principal measurements: universal variables (age, sex, health
service-family practice/paediatrics), variables of morbidity
(resource utilization bands [RUB]) and dependent variables
(visits, episodes and pharmacy cost). The ACG case-mix System
software (version 7.0; n = 106) classiﬁed subjects into a single
category for a given annual resource consumption. A log trans-
formation of dependent variables was carried out to reduce skew
ness of the distribution and make it close to normal. Statistical
software: SPSSWIN, p < 0.05. RESULTS: Study population:
286,450 (Aragon: 49.3%; Balearics: 23.2%; Catalonia: 27.5%),
annual coverage: 75.5% of the population, patient’s mean age:
42.9  23.6 years, percentage of female patients: 54.1%, mean
number of consultations: 7.3  7.1; 6.6  7.0 and 8.0  8.1
correspondingly, p < 0.001. Patient’s case-mix: 55.0% of the
study population was grouped into 10 ACG. A high variability
was observed among regions with differences in the average
values of RUB (2.9  0.8; 2.3  0.8; 2.4  0.8) and pharmacy
cost (€361.67; €242.01; 290.89), p < 0.001. The explanatory
power of the ACG classiﬁcation system was 30.7% (Ln: 41.2%)
for visits, 87.6% (Ln: 87.1%) for episodes and 21.3% (Ln:
39.9%) for pharmacy cost, p < 0.001. CONCLUSIONS: The
fact that patient’s morbidity load is adequately correlated with
attended consultations and pharmacy cost reinforces the appro-
priateness of the ACG system when associating clinical and eco-
nomic information from health care centers in Primary Care. In
consequence, case-mix adjustment must be considered for clini-
cal decision-making and ﬁnancial management in Primary Care.
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COSTS ASSOCIATEDTO ADDITIONALTEMPORAL SICK
LEAVE DAYS INTHE IMSS
Contreras-Hernandez I, Olvera-Gomez JL, Garduño-Espinosa J
Social Security Mexican Institute, Mexico City, Mexico
OBJECTIVES: Financial protection of the afﬁliated workers to
the Social Security Mexican Institute (IMSS) is one of its core
functions; however it also generates outlays to the health system.
This study estimates the associated cost to additional sick leave
days due to medical causes and/or due to inefﬁciencies on the
system. METHODS: A cost study was made from the perspective
of the institution through a prospective cohort of male and
female patients to whom it was prescribed temporal sick leave
days due to diseases not related to the work environment (general
disease), a follow-up was scheduled until their return to their
work place and the cost of medical attention was calculated; this
included ambulatory consult, drugs, lab exams, urgency service
assistance, surgery, hospital time and payment under the concept
of sick leave. All patients must have an estimation of the prob-
able number of recovery days, those who required additional
days were identiﬁed and the causes that triggered a longer lapse.
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